BNTX vs. GSK, TAK, ARGX, ONC, TEVA, ITCI, GMAB, SMMT, RDY, and ASND
Should you be buying BioNTech stock or one of its competitors? The main competitors of BioNTech include GSK (GSK), Takeda Pharmaceutical (TAK), argenx (ARGX), Beigene (ONC), Teva Pharmaceutical Industries (TEVA), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Summit Therapeutics (SMMT), Dr. Reddy's Laboratories (RDY), and Ascendis Pharma A/S (ASND). These companies are all part of the "pharmaceutical products" industry.
BioNTech vs.
BioNTech (NASDAQ:BNTX) and GSK (NYSE:GSK) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation, community ranking and profitability.
15.5% of BioNTech shares are held by institutional investors. Comparatively, 15.7% of GSK shares are held by institutional investors. 19.2% of BioNTech shares are held by company insiders. Comparatively, 10.0% of GSK shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
BioNTech has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500. Comparatively, GSK has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500.
BioNTech presently has a consensus price target of $138.25, suggesting a potential upside of 29.34%. GSK has a consensus price target of $37.38, suggesting a potential downside of 9.50%. Given BioNTech's stronger consensus rating and higher possible upside, equities research analysts plainly believe BioNTech is more favorable than GSK.
In the previous week, BioNTech had 11 more articles in the media than GSK. MarketBeat recorded 22 mentions for BioNTech and 11 mentions for GSK. GSK's average media sentiment score of 0.84 beat BioNTech's score of 0.37 indicating that GSK is being referred to more favorably in the news media.
GSK has a net margin of 8.13% compared to BioNTech's net margin of -15.16%. GSK's return on equity of 48.59% beat BioNTech's return on equity.
GSK has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.
GSK received 673 more outperform votes than BioNTech when rated by MarketBeat users. Likewise, 57.02% of users gave GSK an outperform vote while only 47.04% of users gave BioNTech an outperform vote.
BioNTech pays an annual dividend of $1.53 per share and has a dividend yield of 1.4%. GSK pays an annual dividend of $1.68 per share and has a dividend yield of 4.1%. BioNTech pays out -45.0% of its earnings in the form of a dividend. GSK pays out 86.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.
Summary
GSK beats BioNTech on 13 of the 21 factors compared between the two stocks.
Get BioNTech News Delivered to You Automatically
Sign up to receive the latest news and ratings for BNTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioNTech Competitors List
Related Companies and Tools
This page (NASDAQ:BNTX) was last updated on 6/10/2025 by MarketBeat.com Staff
Buy BNTX Stock Free BNTX Stock Alerts